Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00006473 · ClinicalTrials.gov registry record · Phase 2

Oxaliplatin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

A Phase 2 study, sponsored by National Cancer Institute (NCI).

Completed
Registry status
Phase 2
Development phase
72
Enrollment target

NCT00006473: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).

NCT00006473 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 72 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (46% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add start date to calendar (.ics) →

The verdict

NCT00006473, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).

COMPLETED
Registry status
Phase 2
Development phase
72 participants
Enrollment target

Study Summary

Phase II trial to study the effectiveness of oxaliplatin in treating patients who have relapsed or refractory non-Hodgkin's lymphoma. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die

Primary Outcome

Using a Simon's two-stage model.

Interventions

  • DRUG oxaliplatin

Trial Details

FieldValue
Enrollment Target 72 participants
Start Date 2000-09
Phase Phase 2
National Cancer Institute (NCI)

3,257 total trials

What the finished NCT00006473 record still lists

NCT00006473 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 72 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (46% lower).

The record links to 0 conditions, and to 1 intervention - of which oxaliplatin is the first listed.

NCT00006473 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00006473 about?

NCT00006473 is a clinical study titled "Oxaliplatin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma". Phase II trial to study the effectiveness of oxaliplatin in treating patients who have relapsed or refractory non-Hodgkin's lymphoma. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die

What is the current status of trial NCT00006473?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 72 participants. The study started on 2000-09.

What interventions are being tested in trial NCT00006473?

The interventions under investigation include: oxaliplatin (DRUG).

Who is sponsoring clinical trial NCT00006473?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00006473's enrollment target sits among peer trials

72 925th of 2000 higher than 1,065 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02359253 · 72 participants · NA

    Robot Aided Rehabilitation - Intervention

  • NCT02962661 · 72 participants · Phase 1

    Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines

  • NCT03113643 · 72 participants · Phase 1

    SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

  • NCT03187535 · 72 participants · NA

    Effect of TEAS on PONV After Spinal Surgery

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00006473, the US trial registry maintained by the National Library of Medicine. NCT00006473 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.